Thursday, April 10, 2008 7:01:03 AM
Wednesday April 9, 10:27 am ET
Schering-Plough Ends Partnership With Novacea on Failed Cancer Drug Candidate
SOUTH SAN FRANCISCO, Calif. (AP) -- Schering-Plough Corp. has ended its partnership with Novacea Inc. after their prostate cancer drug candidate Asentar failed, Novacea said Wednesday.
Novacea shares plunged 40 cents, or 14.8 percent, to $2.31 in morning trading. The stock has traded between $2.20 and $17.25 over the last 52 weeks.
The companies ended a late-stage study of the drug in November, citing an "imbalance" of deaths. Patients taking the drug candidate died more often than those taking a standard treatment.
In January, Novacea said it is exploring "strategic options" and retained Cowen and Co. as an adviser.
All Asentar rights will be returned to Novacea. Despite the higher-than-expected number of deaths, the company said it still believes Asentar is a safe drug and called Schering-Plough's decision unexpected.
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM